Breaking News, Collaborations & Alliances

Fractyl Health Partners with Forge for Rejuva Gene Therapy Development

Partnership aims to advance Fractyl Health’s Rejuva pancreatic gene therapy platform for the treatment of patients with obesity and type 2 diabetes.

Author Image

By: Charlie Sternberg

Associate Editor

Forge Biologics, a manufacturer of genetic medicines and a member of the Ajinomoto Bio-Pharma Services group, has entered an AAV development and manufacturing agreement to help advance Fractyl Health’s Rejuva pancreatic gene therapy platform for the treatment of patients with obesity and type 2 diabetes (T2D). “We developed our FUEL platform to provide developers like Fractyl with a more efficient and scalable manufacturing solution to help reach broader patient populations,” said John ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters